Form 4: Day One Biopharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 11,245 shares of common stock at an average price of $16.0326 per share under a pre-arranged trading plan.

Summary

• On November 7, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 11,245 shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on October 10, 2023.
• The shares were sold at prices ranging from $16.00 to $16.10, with a weighted average price of $16.0326.
• Following the transaction, Blackman directly owns 1,085,790 shares of Day One Biopharmaceuticals.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sale was conducted under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company's future.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Rule 10b5-1 trading plans allow insiders to sell shares over a predetermined period, which can mitigate concerns about trading on inside information. The market will often look at the ratio of buys to sells by insiders to determine sentiment.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, depending on market perception of insider selling activity.

Key Dates